UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV
Fifty 1 Labs (OTC: FITY) and UAV Corp (OTC: UMAV) have signed a Memorandum of Understanding on April 07, 2025, forming a strategic partnership to combat biohazards through integrated technology solutions. The collaboration combines UAV Corp's aerial systems with Genetic Networks' GeneScape™ platform to develop real-time detection systems for nuclear, chemical, and biological hazards.
The two-year partnership will focus on integrating 'sniffer' technologies into UAV Corp's airships and drones, with initial testing planned at UAV Corp's Wewahitchka facility. The collaboration leverages both companies' existing Department of Defense contracts and includes developing countermeasures deployable via aerial platforms.
Key initiatives include detection systems integration, countermeasure development, distribution partnership exploration, and joint R&D combining whole-genome analysis with UAV expertise. The partnership builds on FITY's recent SpaceX Fram2 mission experiment studying yeast resistance to microgravity and cosmic radiation.
Fifty 1 Labs (OTC: FITY) e UAV Corp (OTC: UMAV) hanno firmato un Memorandum of Understanding il 7 aprile 2025, formando una partnership strategica per combattere i biohazard attraverso soluzioni tecnologiche integrate. La collaborazione combina i sistemi aerei di UAV Corp con la piattaforma GeneScape™ di Genetic Networks per sviluppare sistemi di rilevamento in tempo reale per pericoli nucleari, chimici e biologici.
La partnership biennale si concentrerà sull'integrazione delle tecnologie 'sniffer' negli dirigibili e droni di UAV Corp, con test iniziali previsti presso la struttura di UAV Corp a Wewahitchka. La collaborazione sfrutta i contratti esistenti delle due aziende con il Dipartimento della Difesa e include lo sviluppo di contromisure utilizzabili tramite piattaforme aeree.
Le iniziative chiave includono l'integrazione dei sistemi di rilevamento, lo sviluppo di contromisure, l'esplorazione di partnership per la distribuzione e la ricerca e sviluppo congiunta che combina l'analisi del genoma completo con l'esperienza di UAV. La partnership si basa sull'esperimento recente di FITY nella missione SpaceX Fram2 che studia la resistenza del lievito alla microgravità e alla radiazione cosmica.
Fifty 1 Labs (OTC: FITY) y UAV Corp (OTC: UMAV) han firmado un Memorando de Entendimiento el 7 de abril de 2025, formando una asociación estratégica para combatir los biohazards a través de soluciones tecnológicas integradas. La colaboración combina los sistemas aéreos de UAV Corp con la plataforma GeneScape™ de Genetic Networks para desarrollar sistemas de detección en tiempo real para peligros nucleares, químicos y biológicos.
La asociación de dos años se centrará en integrar tecnologías 'sniffer' en los dirigibles y drones de UAV Corp, con pruebas iniciales planificadas en la instalación de UAV Corp en Wewahitchka. La colaboración aprovecha los contratos existentes de ambas empresas con el Departamento de Defensa e incluye el desarrollo de contramedidas desplegables a través de plataformas aéreas.
Las iniciativas clave incluyen la integración de sistemas de detección, el desarrollo de contramedidas, la exploración de asociaciones de distribución y la investigación y desarrollo conjunto que combina el análisis del genoma completo con la experiencia de UAV. La asociación se basa en el reciente experimento de FITY en la misión SpaceX Fram2 que estudia la resistencia de la levadura a la microgravedad y la radiación cósmica.
Fifty 1 Labs (OTC: FITY)와 UAV Corp (OTC: UMAV)는 2025년 4월 7일에 양해각서를 체결하여 통합 기술 솔루션을 통해 생물학적 위험을 방지하기 위한 전략적 파트너십을 형성했습니다. 이 협력은 UAV Corp의 항공 시스템과 Genetic Networks의 GeneScape™ 플랫폼을 결합하여 핵, 화학 및 생물학적 위험을 실시간으로 탐지하는 시스템을 개발합니다.
2년간의 파트너십은 UAV Corp의 비행선과 드론에 '스니퍼' 기술을 통합하는 데 중점을 두며, 초기 테스트는 UAV Corp의 Wewahitchka 시설에서 계획되어 있습니다. 이 협력은 두 회사의 기존 국방부 계약을 활용하며, 공중 플랫폼을 통해 배치 가능한 대응책 개발을 포함합니다.
주요 이니셔티브에는 탐지 시스템 통합, 대응책 개발, 유통 파트너십 탐색 및 UAV 전문성과 전체 유전체 분석을 결합한 공동 연구 개발이 포함됩니다. 이 파트너십은 FITY가 최근 수행한 SpaceX Fram2 임무 실험으로, 미세 중력과 우주 방사선에 대한 효모의 저항성을 연구한 것을 기반으로 합니다.
Fifty 1 Labs (OTC: FITY) et UAV Corp (OTC: UMAV) ont signé un protocole d'accord le 7 avril 2025, formant un partenariat stratégique pour lutter contre les biohazards grâce à des solutions technologiques intégrées. La collaboration combine les systèmes aériens de UAV Corp avec la plateforme GeneScape™ de Genetic Networks pour développer des systèmes de détection en temps réel pour les dangers nucléaires, chimiques et biologiques.
Le partenariat de deux ans se concentrera sur l'intégration des technologies 'sniffer' dans les dirigeables et les drones de UAV Corp, avec des tests initiaux prévus dans l'installation de UAV Corp à Wewahitchka. La collaboration tire parti des contrats existants des deux entreprises avec le Département de la Défense et comprend le développement de contre-mesures déployables via des plateformes aériennes.
Les initiatives clés incluent l'intégration des systèmes de détection, le développement de contre-mesures, l'exploration de partenariats de distribution et la recherche et développement conjointe combinant l'analyse du génome entier avec l'expertise de UAV. Le partenariat s'appuie sur l'expérience récente de FITY dans la mission SpaceX Fram2 qui étudie la résistance de la levure à la microgravité et aux radiations cosmiques.
Fifty 1 Labs (OTC: FITY) und UAV Corp (OTC: UMAV) haben am 7. April 2025 ein Memorandum of Understanding unterzeichnet, um eine strategische Partnerschaft zur Bekämpfung von Biohazards durch integrierte Technologielösungen zu bilden. Die Zusammenarbeit kombiniert die Luftsysteme von UAV Corp mit der GeneScape™-Plattform von Genetic Networks, um Echtzeiterkennungssysteme für nukleare, chemische und biologische Gefahren zu entwickeln.
Die zweijährige Partnerschaft konzentriert sich auf die Integration von 'Sniffer'-Technologien in die Luftschiffe und Drohnen von UAV Corp, wobei erste Tests in der Einrichtung von UAV Corp in Wewahitchka geplant sind. Die Zusammenarbeit nutzt die bestehenden Verträge beider Unternehmen mit dem Verteidigungsministerium und umfasst die Entwicklung von Gegenmaßnahmen, die über Luftplattformen eingesetzt werden können.
Zu den wichtigsten Initiativen gehören die Integration von Erkennungssystemen, die Entwicklung von Gegenmaßnahmen, die Erkundung von Vertriebspartnerschaften und gemeinsame F&E, die die Analyse des gesamten Genoms mit UAV-Expertise kombiniert. Die Partnerschaft baut auf dem kürzlichen Experiment von FITY in der SpaceX Fram2-Mission auf, das die Resistenz von Hefe gegen Mikrogravitation und kosmische Strahlung untersucht.
- Strategic partnership combines complementary technologies for defense applications
- Both companies have existing Department of Defense contracts
- Access to Genetic Networks' network of 4,000 generic formulations
- Potential for new defense and space sector contract opportunities
- MOU is non-binding and requires subsequent agreements for specific projects
- Testing timelines and funding details not yet specified
- No immediate revenue impact disclosed
MELBOURNE, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- via IBN - Fifty 1 Labs, Inc. (OTC: FITY), through its wholly owned subsidiary Genetic Networks, a pioneer in genetic perturbation and drug discovery, and UAV Corp (OTC: UMAV), a leader in unmanned aerial vehicle (UAV) technology, are proud to announce the signing of a Memorandum of Understanding (MOU) on April 07, 2025. This strategic partnership aims to develop innovative solutions for detecting and countering biohazards, contaminants, and related threats, leveraging UAV Corp's advanced aerial systems and Genetic Networks' proprietary GeneScape™ platform to enhance public safety, health, and security globally.
The collaboration integrates state-of-the-art "sniffer" technologies into UAV Corp's airships and drones, enabling real-time detection of nuclear, chemical, and biological hazards. Genetic Networks, under the umbrella of Fifty 1 Labs, Inc. (OTC: FITY), contributes its expertise in biohazard identification and drug development—including a patented compound with potential broad-spectrum efficacy against infections—to create countermeasures deployable via UAV Corp's aerial platforms. Initial testing will occur on UAV Corp's airship, currently under completion at its Wewahitchka facility, advancing aerial threat response capabilities.
Both companies are actively engaged in Department of Defense (DoD) contracts, positioning them to assist each other in meeting stringent government requirements. UAV Corp's UAV expertise complements Genetic Networks' advancements in genetic science, offering mutual support for DoD initiatives. On April 1, 2025, FITY announced a groundbreaking yeast experiment launched on SpaceX's Fram2 mission, engineered by Dr. Corey Nislow to study resistance to microgravity and cosmic radiation—data that could inform this collaboration's countermeasure development. Genetic Networks will facilitate introductions between their relationships and UMAV's management team to potentially unlock new opportunities for contracts and collaborations in the defense and space sectors.
"This partnership merges cutting-edge aerial technology with genetic innovation to tackle critical global challenges," said Michael Lawson, CEO of UAV Corp. "By equipping our UAV platforms with advanced detection systems and collaborating with Genetic Networks, we're set to deliver rapid, impactful solutions to biohazard threats worldwide while strengthening our DoD efforts and exploring new avenues."
Gennaro D'Urso, Founder, CEO, and Chairman of Genetic Networks, added, "Teaming up with UAV Corp amplifies the reach of our GeneScape™ platform and drug development efforts, as demonstrated by our recent SpaceX Fram2 mission experiment under Fifty 1 Labs, Inc. (OTC: FITY). Together, we're poised to detect dangers and deploy life-saving countermeasures efficiently, utilizing our supplier network of approximately 4,000 generic formulations and supporting our shared DoD objectives."
Key initiatives outlined in the MOU include:
- Detection Systems: Integrating sniffer technologies into UAV platforms to identify contaminants and biohazards.
- Countermeasures: Developing and distributing compounds to neutralize threats, including radiation and toxic substances, via aerial delivery.
- Distribution Partnership: Exploring Genetic Networks' potential role as an exclusive agent for countermeasure distribution, supported by UAV Corp's aerial capabilities.
- Joint R&D: Combining whole-genome analysis with UAV expertise to refine detection and response strategies.
The two-year collaboration, effective from the signing date, reflects both companies' dedication to innovation and societal benefit. While the MOU serves as a non-binding framework, the parties plan to formalize specific projects and funding through subsequent agreements, with testing timelines to be detailed soon.
"We're thrilled to launch this partnership," Lawson and D'Urso said jointly. "It strengthens our capabilities, aligns our DoD efforts, and positions us to make a tangible impact on global health and security."
About UAV Corp
UAV Corp (OTC: UMAV) is a global leader in unmanned aerial vehicle technology, delivering advanced solutions for security, surveillance, and aerial systems across government, defense, and commercial sectors. Headquartered in Wewahitchka, Florida, UAV Corp is committed to advancing aerial innovation.
Michael Lawson, CEO
Email: mlawson@uavcorp.net
Address: 115 County Road 381, Wewahitchka, FL 32465
Phone: 877-425-1066
Website: www.uavcorp.net
About Genetic Networks
Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), accelerates drug discovery and compound development through its proprietary GeneScape™ platform. The company is dedicated to advancing health solutions through genetic science and strategic partnerships.
Investor Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
Safe Harbor Statement:
The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What are the key objectives of the FITY and UMAV partnership announced in April 2025?
How long is the strategic collaboration between FITY and UMAV set to last?
What specific technologies will FITY and UMAV integrate in their joint venture?
Where will the initial testing of FITY and UMAV's integrated systems take place?
How does FITY's recent SpaceX Fram2 mission relate to the UMAV partnership?
